BioSynTech Malaysia Group Sdn Bhd
199701004244 (419740-A)
No. 12A, Jalan TP 5,
Taman Perindustrian UEP,
47600 Subang Jaya,
Selangor, Malaysia
WhatsApp/Call: +6 016 216 0492
E : info@bstmgroup.com
MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel bioactive compounds, dye reagents, peptides and natural compounds for laboratory and scientific use.
• Over 30,000 bioactive molecules in stock
• Target 500+ key proteins in 20+ signaling pathways
• Quality reports (LC/MS, NMR and HPLC) for each product
• Release more than 500 of the newest biochemicals per month
• Data sheet with detailed biological information
• High purity & competitive prices
• Delivery within 24 hours
CAS No.: 2621928-55-8
MRTX1133
Research Area: KRAS G12D Inhibitor/Diverse Cancers
Solubility: DMSO : 50 mg/mL (83.25 mM; Need ultrasonic)
Ivaltinostat formic
Research Area: HDAC Inhibitor/Prostate Cancer/Cholangiocarcinoma
• An orally active, potent hydroxamate-based pan-HDAC inhibitor with antitumor effects.
• Enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-FU, thereby decreasing cell viability and inducing apoptosis.
• Inhibits deacetylation of histone H3 and tubulin in prostate cancer cells and induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Solubility:
DMSO : 50 mg/mL (105.58 mM; Need ultrasonic)
H2O : 50 mg/mL (105.58 mM; Need ultrasonic)
CAS No.: 1352914-52-3
CR-1-31-B
Research Area: eIF4A Inhibitor/Neuroblastoma/Pancreatic Ductal Adenocarcinoma
• A synthetic Rocaglate and potent eIF4A inhibitor with anticancer and antimalarial activities.
• Exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis.
• Induces apoptosis of neuroblastoma and gallbladder cancer cells.
Solubility: DMSO : 230 mg/mL (453.18 mM; Need ultrasonic)
MRTX9768 hydrochloride
Research Area: PRMT5•MTA Inhibitor/MTAP-del Cancer
• A synthetic lethal-based orally active PRMT5•MTA inhibitor.
• Selectively inhibits symmetric dimethylarginine (SDMA) marks and shows selective antitumor activity in MTAP-del tumor cells while sparing MTAP-WT cells.
Solubility:
DMSO : 90 mg/mL (195.27 mM; Need ultrasonic)
H2O : 40 mg/mL (86.79 mM; Need ultrasonic)
CAS No.: 357425-68-4
CP-601932
Research Area: α3β4 nAChR Agonist/Alcohol Dependence
• High-affinity partial agonist at α3β4 nAChR (Ki=21 nM; EC50=~3 μM), has the same high-binding affinity at α4β2 nAChR (Ki=21 nM) and can penetrate the CNS.
• Selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure.
Solubility: DMSO : 200 mg/mL (880.17 mM; Need ultrasonic)
CAS No.: 245520-69-8
SCH79797
Research Area: PAR1 Antagonist/Myocardial Ischemia/Reperfusion Injury
• Highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist.
• Inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 (IC50=70 nM; Ki=35 nM) and inhibits thrombin-induced platelet aggregation (IC50=3 μM).
• Limits myocardial ischemia/reperfusion injury in rat hearts.
Solubility: DMSO : 50 mg/mL (134.60 mM; Need ultrasonic)
Key Features:
Recent Publications Citing Use of MCE Products
![]() |
Nat Nanotechnol. 2021 Nov;16(11):1260-1270.
Cell Metab. 2021 Nov 2;33(11):2247-2259.e6.
Cell Metab. 2021 Dec 7;33(12):2355-2366.e8.
Cancer Cell. 2021 Nov 8;39(11):1531-1547.e10.
Cell Signaling Pathways